Clinical Trial Update: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers a BCMA-targeted CAR-T cell therapy being explored for relapsed/refractory multiple myeloma and plasma cell neoplasms; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• BCMA-targeted CAR-T cell therapy (investigational)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1, Phase 2 | Status: RECRUITING